{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T02:50:56Z","timestamp":1795229456905,"version":"4.10.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA258239"],"award-info":[{"award-number":["R01 CA258239"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA108961"],"award-info":[{"award-number":["P50 CA108961"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA123839"],"award-info":[{"award-number":["R21 CA123839"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100008222","name":"The Ben & Catherine Ivy Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008222","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Measles virus (MV) vaccine strains have shown significant preclinical antitumor activity against glioblastoma (GBM), the most lethal glioma histology. In this first in human trial (NCT00390299), a carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA), was administered in recurrent GBM patients either at the resection cavity (Group A), or, intratumorally on day 1, followed by a second dose administered in the resection cavity after tumor resection on day 5 (Group B). A total of 22 patients received study treatment, 9 in Group A and 13 in Group B. Primary endpoint was safety and toxicity: treatment was well tolerated with no dose-limiting toxicity being observed up to the maximum feasible dose (2\u00d710<jats:sup>7<\/jats:sup> TCID50). Median OS, a secondary endpoint, was 11.6 mo and one year survival was 45.5% comparing favorably with contemporary controls. Other secondary endpoints included assessment of viremia, MV replication and shedding, humoral and cellular immune response to the injected virus. A 22 interferon stimulated gene (ISG) diagonal linear discriminate analysis (DLDA) classification algorithm in a post-hoc analysis was found to be inversely (R\u2009=\u2009\u22120.6, p\u2009=\u20090.04) correlated with viral replication and tumor microenvironment remodeling including proinflammatory changes and CD8\u2009+\u2009T cell infiltration in post treatment samples. This data supports that oncolytic MV derivatives warrant further clinical investigation and that an ISG-based DLDA algorithm can provide the basis for treatment personalization.<\/jats:p>","DOI":"10.1038\/s41467-023-43076-7","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T17:03:32Z","timestamp":1705079012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8014-786X","authenticated-orcid":false,"given":"Evanthia","family":"Galanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4565-5767","authenticated-orcid":false,"given":"Katharine E.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1542-9726","authenticated-orcid":false,"given":"S.","family":"Keith Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheyne B.","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiomara W.","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon H.","family":"Uhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Federspiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey A.","family":"Leontovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Aderca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly B.","family":"Viker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Hammack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randolph S.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven I.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Buckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Lachance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-3045","authenticated-orcid":false,"given":"Terry C.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2757-6782","authenticated-orcid":false,"given":"Caterina","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Raghunathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ianko D.","family":"Iankov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian F.","family":"Parney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"43076_CR1","doi-asserted-by":"publisher","first-page":"e0198581","DOI":"10.1371\/journal.pone.0198581","volume":"13","author":"A Bohn","year":"2018","unstructured":"Bohn, A., Braley, A., Rodriguez de la Vega, P., Zevallos, J. C. & Barengo, N. C. The association between race and survival in glioblastoma patients in the US: a retrospective cohort study. PLoS ONE 13, e0198581 (2018).","journal-title":"PLoS ONE"},{"key":"43076_CR2","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","volume":"23","author":"JP Thakkar","year":"2014","unstructured":"Thakkar, J. P. et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol. Biomark. Prev. 23, 1985\u20131996 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"43076_CR3","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert, M. R. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J. Clin. Oncol. 31, 4085\u20134091 (2013).","journal-title":"J. Clin. Oncol."},{"key":"43076_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"New Engl. J. Med."},{"key":"43076_CR5","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. J. Am. Med. Assoc. 318, 2306\u20132316 (2017).","journal-title":"J. Am. Med. Assoc."},{"key":"43076_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11060-017-2685-4","volume":"136","author":"E Audureau","year":"2018","unstructured":"Audureau, E. et al. Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model. J. Neurooncol. 136, 565\u2013576 (2018).","journal-title":"J. Neurooncol."},{"key":"43076_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.wneu.2011.05.056","volume":"77","author":"JK Burkhardt","year":"2012","unstructured":"Burkhardt, J. K. et al. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg. 77, 130\u2013134 (2012).","journal-title":"World Neurosurg."},{"key":"43076_CR8","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1002\/cncr.30838","volume":"123","author":"KM Field","year":"2017","unstructured":"Field, K. M. et al. The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: results from a prospective clinical trial (CABARET). Cancer 123, 3576\u20133582 (2017).","journal-title":"Cancer"},{"key":"43076_CR9","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","volume":"17","author":"ET Wong","year":"1999","unstructured":"Wong, E. T. et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J. Clin. Oncol. 17, 2572\u20132578 (1999).","journal-title":"J. Clin. Oncol."},{"key":"43076_CR10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6, 1003\u20131010 (2020).","journal-title":"JAMA Oncol."},{"key":"43076_CR11","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","volume":"15","author":"M Weller","year":"2014","unstructured":"Weller, M. et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 15, e395\u2013e403 (2014).","journal-title":"Lancet Oncol."},{"key":"43076_CR12","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim, M. et al. Phase 3 trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24, 1935\u20131949 (2022).","journal-title":"Neuro Oncol."},{"key":"43076_CR13","doi-asserted-by":"crossref","unstructured":"Omuro, A. et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial. Neuro Oncol. 25, 123\u2013134 (2022).","DOI":"10.1093\/neuonc\/noac099"},{"key":"43076_CR14","doi-asserted-by":"publisher","first-page":"108103","DOI":"10.1016\/j.pharmthera.2021.108103","volume":"236","author":"S Feola","year":"2021","unstructured":"Feola, S., Russo, S., Yl\u00f6sm\u00e4ki, E. & Cerullo, V. Oncolytic ImmunoViroTherapy: a long history of crosstalk between viruses and immune system for cancer treatment. Pharm. Ther. 236, 108103 (2021).","journal-title":"Pharm. Ther."},{"key":"43076_CR15","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.3390\/cancers13215452","volume":"13","author":"MM Rahman","year":"2021","unstructured":"Rahman, M. M. & McFadden, G. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers 13, 5452 (2021).","journal-title":"Cancers"},{"key":"43076_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1517\/14712598.2013.749851","volume":"13","author":"P Msaouel","year":"2013","unstructured":"Msaouel, P., Opyrchal, M., Domingo Musibay, E. & Galanis, E. Oncolytic measles virus strains as novel anticancer agents. Expert Opin. Biol. Ther. 13, 483\u2013502 (2013).","journal-title":"Expert Opin. Biol. Ther."},{"key":"43076_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14712598.2017.1288713","volume":"17","author":"S Robinson","year":"2017","unstructured":"Robinson, S. & Galanis, E. Potential and clinical translation of oncolytic measles viruses. Expert Opin. Biol. Ther. 17, 353\u2013363 (2017).","journal-title":"Expert Opin. Biol. Ther."},{"key":"43076_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1568009617666170222125035","volume":"18","author":"P Msaouel","year":"2018","unstructured":"Msaouel, P. et al. Clinical trials with oncolytic measles virus: current status and future prospects. Curr. Cancer Drug Targets 18, 177\u2013187 (2018).","journal-title":"Curr. Cancer Drug Targets"},{"key":"43076_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1517\/14712598.8.2.213","volume":"8","author":"C Allen","year":"2008","unstructured":"Allen, C. et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin. Biol. Ther. 8, 213\u2013220 (2008).","journal-title":"Expert Opin. Biol. Ther."},{"key":"43076_CR20","first-page":"493","volume":"19","author":"J Hardcastle","year":"2017","unstructured":"Hardcastle, J. et al. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol. 19, 493\u2013502 (2017).","journal-title":"Neuro Oncol."},{"key":"43076_CR21","first-page":"2462","volume":"63","author":"LK Phuong","year":"2003","unstructured":"Phuong, L. K. et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63, 2462\u20132469 (2003).","journal-title":"Cancer Res."},{"key":"43076_CR22","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1038\/leu.2017.120","volume":"31","author":"A Dispenzieri","year":"2017","unstructured":"Dispenzieri, A. et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia 31, 2791\u20132798 (2017).","journal-title":"Leukemia"},{"key":"43076_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","volume":"70","author":"E Galanis","year":"2010","unstructured":"Galanis, E. et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70, 875\u2013882 (2010).","journal-title":"Cancer Res."},{"key":"43076_CR24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/jnci\/djy033","volume":"110","author":"C Kurokawa","year":"2018","unstructured":"Kurokawa, C. et al. Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy. J. Natl. Cancer Inst. 110, 1123\u20131132 (2018).","journal-title":"J. Natl. Cancer Inst."},{"key":"43076_CR25","unstructured":"Griffin, D. E., Howley, P. M. & Knipe, D. M. Fields\u2019 Virology (Lippincott Williams & Wilkins, 2007)."},{"key":"43076_CR26","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s007050170121","volume":"146","author":"H Okada","year":"2001","unstructured":"Okada, H. et al. Comparative analysis of host responses related to immunosuppression between measles patients and vaccine recipients with live attenuated measles vaccines. Arch. Virol. 146, 859\u2013874 (2001).","journal-title":"Arch. Virol."},{"key":"43076_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim, M., Xia, Y., Bettegowda, C. & Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422\u2013442 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"43076_CR28","doi-asserted-by":"publisher","first-page":"vi29","DOI":"10.1093\/neuonc\/nox168.110","volume":"19","author":"O Bloch","year":"2017","unstructured":"Bloch, O., Shi, Q. & Anderson, S. K. Alliance A071101: a phase II randomized trial comparing the efficacy of heat shock protein peptide complex-96 (HSPPC-96) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma. Neuro Oncol. 19, vi29 (2017).","journal-title":"Neuro Oncol."},{"key":"43076_CR29","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/neuonc\/nov104","volume":"17","author":"KM Field","year":"2015","unstructured":"Field, K. M. et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol. 17, 1504\u20131513 (2015).","journal-title":"Neuro Oncol."},{"key":"43076_CR30","doi-asserted-by":"publisher","first-page":"vdac041","DOI":"10.1093\/noajnl\/vdac041","volume":"4","author":"E Galanis","year":"2022","unstructured":"Galanis, E. et al. Phase I\/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-oncol. Adv. 4, vdac041 (2022).","journal-title":"Neuro-oncol. Adv."},{"key":"43076_CR31","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1002\/cncr.32340","volume":"125","author":"E Galanis","year":"2019","unstructured":"Galanis, E. et al. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance\/North Central Cancer Treatment Group N0872. Cancer 125, 3790\u20133800 (2019).","journal-title":"Cancer"},{"key":"43076_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang, F. F. et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J. Clin. Oncol. 36, 1419\u20131427 (2018).","journal-title":"J. Clin. Oncol."},{"key":"43076_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. New Engl. J. Med. 379, 150\u2013161 (2018).","journal-title":"New Engl. J. Med."},{"key":"43076_CR34","doi-asserted-by":"publisher","first-page":"341ra375","DOI":"10.1126\/scitranslmed.aad9784","volume":"8","author":"TF Cloughesy","year":"2016","unstructured":"Cloughesy, T. F. et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci. Transl. Med. 8, 341ra375 (2016).","journal-title":"Sci. Transl. Med."},{"key":"43076_CR35","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","volume":"6","author":"TF Cloughesy","year":"2020","unstructured":"Cloughesy, T. F. et al. Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial. JAMA Oncol. 6, 1939\u20131946 (2020).","journal-title":"JAMA Oncol."},{"key":"43076_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cyto.2017.05.024","volume":"97","author":"A Showalter","year":"2017","unstructured":"Showalter, A. et al. Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine 97, 123\u2013132 (2017).","journal-title":"Cytokine"},{"key":"43076_CR37","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17, 559\u2013572 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"43076_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev.immunol.19.1.65","volume":"19","author":"LG Guidotti","year":"2001","unstructured":"Guidotti, L. G. & Chisari, F. V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19, 65\u201391 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"43076_CR39","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo, T. et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med. 28, 1630\u20131639 (2022).","journal-title":"Nat. Med."},{"key":"43076_CR40","doi-asserted-by":"publisher","first-page":"e141614","DOI":"10.1172\/JCI141614","volume":"131","author":"E Panagioti","year":"2021","unstructured":"Panagioti, E. et al. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. J. Clin. Investig. 131, e141614 (2021).","journal-title":"J. Clin. Investig."},{"key":"43076_CR41","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","volume":"35","author":"PY Wen","year":"2017","unstructured":"Wen, P. Y. et al. Response assessment in neuro-oncology clinical trials. J. Clin. Oncol. 35, 2439\u20132449 (2017).","journal-title":"J. Clin. Oncol."},{"key":"43076_CR42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"43076_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0036","volume":"3","author":"S Dudoit","year":"2002","unstructured":"Dudoit, S. & Fridlyand, J. A prediction-based resampling method for estimating the number of clusters in a dataset. Genome Biol. 3, Research0036 (2002).","journal-title":"Genome Biol."},{"key":"43076_CR44","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1200\/JCO.2006.05.6861","volume":"24","author":"KR Hess","year":"2006","unstructured":"Hess, K. R. et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24, 4236\u20134244 (2006).","journal-title":"J. Clin. Oncol."},{"key":"43076_CR45","doi-asserted-by":"publisher","first-page":"W317","DOI":"10.1093\/nar\/gkp416","volume":"37","author":"R Nogales-Cadenas","year":"2009","unstructured":"Nogales-Cadenas, R. et al. GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res. 37, W317\u2013W322 (2009).","journal-title":"Nucleic Acids Res."},{"key":"43076_CR46","doi-asserted-by":"publisher","first-page":"W478","DOI":"10.1093\/nar\/gks402","volume":"40","author":"D Tabas-Madrid","year":"2012","unstructured":"Tabas-Madrid, D., Nogales-Cadenas, R. & Pascual-Montano, A. GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res. 40, W478\u2013W483 (2012).","journal-title":"Nucleic Acids Res."},{"key":"43076_CR47","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, (Vienna, Austria, 2022)."},{"key":"43076_CR48","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2307\/2531693","volume":"45","author":"BE Storer","year":"1989","unstructured":"Storer, B. E. Design and analysis of phase I clinical trials. Biometrics 45, 925\u2013937 (1989).","journal-title":"Biometrics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43076-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43076-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43076-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T17:05:25Z","timestamp":1705079125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43076-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["43076"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-43076-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"25 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests or other interests that might be perceived to influence the interpretation of the article. Outside of this submission, EG has received honoraria for advisory board participation from Kiyatec, Inc. (personal compensation) and Karyopharm Therapeutics, Inc. for Data Safety and Monitoring Board participation (compensation to the employer). Her institution has received grant funding from Servier Pharmaceuticals LLC (formerly Agios Pharmaceuticals, Inc.), Celgene, MedImmune, Inc. and Tracon Pharmaceuticals. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"493"}}